摘要
注意力缺陷和多动症(ADHD)症状的特征在于粗心和极度活跃。它是一种常见的儿童神经发育障碍,往往持续到成年。用精神振奋药物改善ADHD症状被认为是一种矛盾的镇静作用。精神兴奋药盐酸哌甲酯控制片(MPH)目前被用作治疗ADHD的一线药物。最近的研究提到注意改变多巴胺介导的神经传递多动症,特别是通过多巴胺转运蛋白(DAT)的再摄取。这种假设是由观察到的DAT基因敲除小鼠表现出的显著极度活跃所支持,这种极度活跃对急性MPH治疗敏感。但是,其他与多动症有关行为尚未完全阐明。在本研究中,我们观察到了DAT基因敲除小鼠在新环境中的梭箱回避行为和极度活跃的学习障碍。盐酸哌甲酯控释片使这些行为正常化且增加大鼠悬尾实验中的躲避行为。有趣的是,有效剂量的MPH增加前额皮质的细胞外多巴胺,而不增加纹状体的,说明在ADHD中前额多巴胺的改变重要性。运用啮齿动物模型如DAT敲除小鼠的研究可能对阐明多动症的病理生理学有用。
关键词: ADHD,多巴胺转运蛋白,额叶皮质,敲除,学习,哌醋甲酯,去甲肾上腺素转运蛋白
Current Molecular Medicine
Title:Improvement of Learning and Increase in Dopamine Level in the Frontal Cortex by Methylphenidate in Mice Lacking Dopamine Transporter
Volume: 15 Issue: 3
Author(s): Y. Takamatsu, Y. Hagino, A. Sato, T. Takahashi, S.Y. Nagasawa, Y. Kubo, M. Mizuguchi, G.R. Uhl, I. Sora and K. Ikeda
Affiliation:
关键词: ADHD,多巴胺转运蛋白,额叶皮质,敲除,学习,哌醋甲酯,去甲肾上腺素转运蛋白
摘要: The symptoms of attention-deficit/hyperactivity disorder (ADHD) are characterized by inattention and hyperactivity-impulsivity. It is a common childhood neurodevelopmental disorder that often persists into adulthood. Improvements in ADHD symptoms using psychostimulants have been recognized as a paradoxical calming effect. The psychostimulant methylphenidate (MPH) is currently used as the first-line medication for the management of ADHD. Recent studies have drawn attention to altered dopamine-mediated neurotransmission in ADHD, particularly reuptake by the dopamine transporter (DAT). This hypothesis is supported by the observation that DAT knockout mice exhibit marked hyperactivity that is responsive to acute MPH treatment. However, other behaviors relevant to ADHD have not been fully clarified. In the present study, we observed learning impairment in shuttle-box avoidance behavior together with hyperactivity in a novel environment in DAT knockout mice. Methylphenidate normalized these behaviors and enhanced escape activity in the tail suspension test. Interestingly, the effective dose of MPH increased extracellular dopamine in the prefrontal cortex but not striatum, suggesting an important role for changes in prefrontal dopamine in ADHD. Research that uses rodent models such as DAT knockout mice may be useful for elucidating the pathophysiology of ADHD.
Export Options
About this article
Cite this article as:
Y. Takamatsu, Y. Hagino, A. Sato, T. Takahashi, S.Y. Nagasawa, Y. Kubo, M. Mizuguchi, G.R. Uhl, I. Sora and K. Ikeda , Improvement of Learning and Increase in Dopamine Level in the Frontal Cortex by Methylphenidate in Mice Lacking Dopamine Transporter, Current Molecular Medicine 2015; 15 (3) . https://dx.doi.org/10.2174/1566524015666150330144018
DOI https://dx.doi.org/10.2174/1566524015666150330144018 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Suicide in Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Nitric Oxide in Asthma Therapy
Current Pharmaceutical Design Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design Cannabinoid 1 (CB1) Receptor - Pharmacology, Role in Pain and Recent Developments in Emerging CB1 Agonists
CNS & Neurological Disorders - Drug Targets Quantitative Gait Disturbances in Older Adults with Cognitive Impairments
Current Pharmaceutical Design Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Current Psychiatry Reviews Modulation of Dopamine Transmission by 5HT2C and 5HT3 Receptors: A Role in the Antidepressant Response
Current Drug Targets An Overview of the Pharmacogenetics and Molecular Genetics of ADHD
Current Pharmacogenomics Changes in Speech Chunking in Reading Aloud is a Marker of Mild Cognitive Impairment and Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry GCH1, BH4 and Pain
Current Pharmaceutical Biotechnology Molecular Pharmacology of the Glycine Receptor Chloride Channel
Current Pharmaceutical Design The Beneficial Effect of Rice Bran Extract Against Rotenone-Induced Experimental Parkinson’s Disease in Rats
Current Molecular Pharmacology